Pete Stavropoulos

Stock Analyst at Cantor Fitzgerald

(3.00)
# 1,484
Out of 4,987 analysts
50
Total ratings
37.5%
Success rate
4.32%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Pete Stavropoulos

Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.33
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $44.68
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107$100
Current: $24.54
Upside: +307.50%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.26
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.05
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.46
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.38
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.95
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.53
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.44
Upside: -
Initiates: Overweight
Price Target: n/a
Current: $38.88
Upside: -
Reiterates: Overweight
Price Target: $5
Current: $7.71
Upside: -35.15%
Reiterates: Overweight
Price Target: $13
Current: $1.25
Upside: +940.00%
Reiterates: Overweight
Price Target: $8
Current: $8.99
Upside: -11.01%